Inzaule S, Easterbrook P, Latona A, Ford N, Irving W, Matthews P
Clin Infect Dis. 2024; 79(6):1437-1446.
PMID: 39361017
PMC: 11650865.
DOI: 10.1093/cid/ciae431.
Dietz J, Graf C, Berg C, Port K, Deterding K, Buggisch P
JHEP Rep. 2024; 6(7):101072.
PMID: 39006503
PMC: 11246049.
DOI: 10.1016/j.jhepr.2024.101072.
Mbisa J, Lapp Z, Bibby D, Phillips L, Manso C, Packer S
J Infect Dis. 2024; 230(6):e1254-e1262.
PMID: 38717937
PMC: 11646602.
DOI: 10.1093/infdis/jiae253.
Graf C, DAmbrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J
JHEP Rep. 2024; 6(3):100994.
PMID: 38357421
PMC: 10865039.
DOI: 10.1016/j.jhepr.2023.100994.
Flower B, Hung L, McCabe L, Ansari M, Le Ngoc C, Vo Thi T
Elife. 2023; 12.
PMID: 36622106
PMC: 9870305.
DOI: 10.7554/eLife.81801.
Hepatitis C subtyping assay failure in UK patients born in sub-Saharan Africa: Implications for global treatment and elimination.
Adeboyejo K, King B, Tsoleridis T, Tarr A, McLauchlan J, Irving W
J Med Virol. 2022; 95(1):e28178.
PMID: 36168235
PMC: 10092547.
DOI: 10.1002/jmv.28178.
Effects of Achieving Sustained Virologic Response after Direct-Acting Antiviral Agents on Long-Term Liver Fibrosis in Diabetics vs. in Non-Diabetic Patients with Chronic Hepatitis C Infection.
Popescu M, Firu D, Padureanu V, Marginean C, Mitrut R, Arsene A
Biomedicines. 2022; 10(9).
PMID: 36140194
PMC: 9495608.
DOI: 10.3390/biomedicines10092093.
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.
Smith D, Fernandez-Antunez C, Magri A, Bowden R, Chaturvedi N, Fellay J
Nat Commun. 2021; 12(1):6105.
PMID: 34671027
PMC: 8528821.
DOI: 10.1038/s41467-021-25649-6.
Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?.
Solitano V, Torres M, Pugliese N, Aghemo A
Viruses. 2021; 13(6).
PMID: 34205966
PMC: 8228389.
DOI: 10.3390/v13061048.
Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson E
J Hepatol. 2021; 75(2):462-473.
PMID: 33974951
PMC: 8310923.
DOI: 10.1016/j.jhep.2021.04.045.
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
Aranday-Cortes E, McClure C, Davis C, Irving W, Adeboyejo K, Tong L
J Infect Dis. 2021; 226(6):995-1004.
PMID: 33668068
PMC: 9492310.
DOI: 10.1093/infdis/jiab110.
Autophagy in HCV Replication and Protein Trafficking.
Chu J, Ou J
Int J Mol Sci. 2021; 22(3).
PMID: 33499186
PMC: 7865906.
DOI: 10.3390/ijms22031089.
Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S, Fernandez-Antunez C, Mikkelsen L, Pedersen J, Li Y, Bukh J
Antimicrob Agents Chemother. 2019; 64(3).
PMID: 31818814
PMC: 7038289.
DOI: 10.1128/AAC.01888-19.
Relevance of Rab Proteins for the Life Cycle of Hepatitis C Virus.
Elgner F, Hildt E, Bender D
Front Cell Dev Biol. 2018; 6:166.
PMID: 30564577
PMC: 6288913.
DOI: 10.3389/fcell.2018.00166.
Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.
Davis C, Mgomella G, da Silva Filipe A, Frost E, Giroux G, Hughes J
Hepatology. 2018; 69(4):1426-1441.
PMID: 30387174
PMC: 6492010.
DOI: 10.1002/hep.30342.
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.
Baumert T, Berg T, Lim J, Nelson D
Gastroenterology. 2018; 156(2):431-445.
PMID: 30342035
PMC: 6446912.
DOI: 10.1053/j.gastro.2018.10.024.
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Smith D, Magri A, Bonsall D, Ip C, Trebes A, Brown A
Hepatology. 2018; 69(5):1861-1872.
PMID: 29425396
PMC: 6492296.
DOI: 10.1002/hep.29837.
